IntoCell Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 46

Employees

  • Stock Symbol
  • 287840

Stock Symbol

  • Share Price
  • $9.66
  • (As of Friday Closing)

IntoCell General Information

Description

Intocell Inc possesses independent linker platform technology in the ADC (Antibody-Drug Conjugate) field, which is in the spotlight in the anticancer drug market. The company is researching linker technology that conjugates with drugs and drugs for ADC. The business model of the company is to continuously secure sales through platform technology export that allows linker platform technology to be applied to partner companies' antibodies, and technology export of ADC pipelines.

Contact Information

Website
www.intocell.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 101, Sinildong-ro, Daedeok-gu
  • Sinil-dong 1688-11
  • Daejeon, Daedeok
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Vertical(s)
Life Sciences
Corporate Office
  • 101, Sinildong-ro, Daedeok-gu
  • Sinil-dong 1688-11
  • Daejeon, Daedeok
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IntoCell Stock Performance

As of 13-Nov-2026, IntoCell’s stock price is $9.66. Its current market cap is $145M with 15M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.66 $9.95 $9.04 - $51.05 $145M 15M 35.4K -$0.43

IntoCell Financials Summary

As of 30-Jun-2026, IntoCell has a trailing 12-month revenue of $2.2M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 220,556 578,682
Revenue 2,199 1,616 2,129 1,236
EBITDA (6,384) (7,264) (6,954) (12,654)
Net Income (6,509) (7,451) (7,265) (12,831)
Total Assets 23,661 28,648 16,098 20,132
Total Debt 6,628 7,093 6,829 7,772
Public Fundamental Data provided by Morningstar, Inc. disclaimer

IntoCell Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore IntoCell‘s full profile, request access.

Request a free trial

IntoCell Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Intocell Inc possesses independent linker platform technology in the ADC (Antibody-Drug Conjugate) field, which is in th
Drug Discovery
Daejeon, South Korea
46 As of 2025

Daejeon, South Korea
 

Bothell, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IntoCell Competitors (2)

One of IntoCell’s 2 competitors is LigaChem Biosciences, a Formerly VC-backed company based in Daejeon, South Korea.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
LigaChem Biosciences Formerly VC-backed Daejeon, South Korea
Seagen Formerly VC-backed Bothell, WA
You’re viewing 2 of 2 competitors. Get the full list »

IntoCell Patents

  • 72

    Total Documents Applications and Grants

  • Total Patents Families

  • 29

    Granted

  • 24

    Pending

  • Expiring in next 12 mo

IntoCell Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4832918-A1 Antibody drug conjugates comprising camptothecin derivatives and uses thereof Pending 27-Dec-2023
US-20250213712-A1 Antibody drug conjugates comprising camptothecin derivatives and uses thereof Pending 27-Dec-2023
WO-2025141316-A1 Antibody drug conjugates comprising camptothecin derivatives and uses thereof Inactive 27-Dec-2023
EP-4452328-A1 Antibody drug conjugates comprising toxins with polar groups and uses thereof Pending 21-Dec-2021
US-20230190939-A1 Antibody drug conjugates comprising toxins with polar groups and uses thereof Pending 21-Dec-2021 A61K47/549
To view IntoCell’s complete patent history, request access »

IntoCell Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IntoCell ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view IntoCell’s complete esg history, request access »

IntoCell FAQs

  • When was IntoCell founded?

    IntoCell was founded in 2015.

  • Where is IntoCell headquartered?

    IntoCell is headquartered in Daejeon, South Korea.

  • What is the size of IntoCell?

    IntoCell has 46 total employees.

  • What industry is IntoCell in?

    IntoCell’s primary industry is Drug Discovery.

  • Is IntoCell a private or public company?

    IntoCell is a Public company.

  • What is IntoCell’s stock symbol?

    The ticker symbol for IntoCell is 287840.

  • What is the current stock price of IntoCell?

    As of 13-Nov-2026 the stock price of IntoCell is $9.66.

  • What is the current market cap of IntoCell?

    The current market capitalization of IntoCell is $145M.

  • What is IntoCell’s current revenue?

    The trailing twelve month revenue for IntoCell is $2.2M.

  • Who are IntoCell’s competitors?

    LigaChem Biosciences and Seagen are competitors of IntoCell.

  • What is IntoCell’s annual earnings per share (EPS)?

    IntoCell’s EPS for 12 months was -$0.43.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process